Results 111 to 120 of about 58,249 (234)
Continuous infusion ceftazidime in intensive care: a randomized controlled trial
, 1999 We randomized 18 critically ill patients to receive ceftazidime 6 g/day by continuous infusion or bolus dosing (2 g 8 hourly), each with a loading dose of 12 mg/kg ceftazidime.
Gomersall, CD +4 more
core +1 more source
Mateusz Szymański,1,2 Małgorzata M Skiba,2 Małgorzata Piasecka,2 Alina Olender3 1Human Anatomy Department, Medical University, Lublin, Poland; 2Intensive Care Unit, Stefan Cardinal Wyszyński District Specialist Hospital ...
Szymański M +3 more
core
, 2010 Objective: To evaluate cefditoren in inducer-substrate combinations to screen for AmpC induction. Methods: 100 clinical isolates (25 P. aeruginosa, 25 E. cloacae, 14 M. morganii, 13 S. marcescens, 12 C. freundii, 7 P. rettgeri, and 4 E.
Coronel, Pilar +8 more
core
Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants
, 2018 Ceftazidime, a third-generation cephalosporin, can be used for the treatment of adults and children with infections due to susceptible bacteria. To date, the pediatric pharmacokinetic data are limited in infants, and therefore we aimed to evaluate the ...
Totsapol Jirasomprasert +8 more
core +1 more source
Environmental Microbiology Reports, Volume 18, Issue 3, June 2026.Antimicrobial resistance and biofilm‐specific tolerance of cultivable Pseudomonas, Bacillus, Brevibacillus and Paenibacillus isolated from deep‐sea sediments of a methane‐seep area off the Southern Brazilian coast. These findings underscore the role of deep‐sea environments as potential reservoirs for antimicrobial‐resistant bacteria (ARB) and ...
Amanda Simão Dias +2 more
wiley +1 more source
Contact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli +8 more
wiley +1 more source
Polish Journal of MicrobiologyThe novel antibiotic ceftazidime-avibactam was introduced in Korea in 2023. This study evaluated the in vitro susceptibility of Pseudomonas aeruginosa isolates from a community-based hospital to various antibiotics, including ceftazidime-avibactam.
Lee Hyo-Jin +6 more
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Antimicrobial resistance (AMR) has become a global health crisis, with Klebsiella pneumoniae (K. pneumoniae) emerging as a major driver of AMR and a leading cause of urinary tract infections (UTIs). Mesenchymal stem cell (MSC)‐derived secretomes have gained attention for their antimicrobial properties.
Leen Ali +3 more
wiley +1 more source
The determination of the ionization profile of ceftazidime
, 2022 The ionization constants (pKa) of ceftazidime, third generation cephalosporin, were determined by potentiometry. Ceftazidime is an ampholyte with four ionizable centers, three acidic centers (two carboxyl groups and amide group) and one basic center ...
Popović-Nikolić, Marija +2 more
core
Sphingobium yanoikuyae Bacteremia, Japan
Emerging Infectious DiseasesWe report a case of Sphingobium yanoikuyae bacteremia in an 89-year-old patient in Japan. No standard antimicrobial regimen has been established for S. yanoikuyae infections.
Yayoi Miyamatsu +2 more
doaj +1 more source